hotspot -WSS

hotspot

author：knowledge 2025-09-03 03:31:58 - browse：9756

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Heart disease in astronauts blamed on cosmic radiation

entertainment

WSS

Erich Jarvis studies song birds to learn about human stuttering

Bring on the sabbaticals for nurses

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

What Kate Middleton's cancer revelation might teach the world

CRISPR technology availability, affordability needs to be expanded

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

leisure time

hotspot

knowledge

New air purifier tech could be key to improving indoor air quality

Personalized medicine goes far beyond genetics

Psychedelics group wrestles with new pharma identity

Asbestos ban is immediate, but health effects will linger for decades

As demand for Covid shots wanes, Moderna seeks its next success

Personalized medicine goes far beyond genetics

Heart attack and stroke risk calculators need revising

Alnylam reports growth in sales of rare disease treatments

Medical records are filled with copy

This gene therapy has record $4.25 million price. It's saved children.

knowledge

Diabetes management: Digital health tools fall short, study says

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Late stage cancers on the rise after pandemic delayed screenings

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Personalized medicine goes far beyond genetics

Yancopoulos of Regeneron works to expand Dupixent success

entertainment

hotspot

entertainment

knowledge